1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar
|
2
|
Ettinger DS, Akerley W, Bepler G, Blum MG,
Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, et
al: NCCN Non-Small Cell Lung Cancer Panel Members: Non-small cell
lung cancer. J Natl Compr Canc Netw. 8:740–801. 2010. View Article : Google Scholar
|
3
|
Pastorino U: Lung cancer screening. Br J
Cancer. 102:1681–1686. 2010. View Article : Google Scholar
|
4
|
Gettinger S and Lynch T: A decade of
advances in treatment for advanced non-small cell lung cancer. Clin
Chest Med. 32:839–851. 2011. View Article : Google Scholar
|
5
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar
|
6
|
Zhu CQ, da Cunha Santos G, Ding K,
Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire
JA, et al: National Cancer Institute of Canada Clinical Trials
Group Study BR.21: Role of KRAS and EGFR as biomarkers of response
to erlotinib in National Cancer Institute of Canada Clinical Trials
Group Study BR.21. J Clin Oncol. 26:4268–4275. 2008. View Article : Google Scholar
|
7
|
Horiike A, Yamamoto N, Tanaka H,
Yanagitani N, Kudo K, Ohyanagi F, Ono A, Naito T, Murakami H, Horai
T, et al: Phase II study of erlotinib for acquired resistance to
gefitinib in patients with advanced non-small cell lung cancer.
Anticancer Res. 34:1975–1981. 2014.
|
8
|
Lee JY, Sun JM, Lim SH, Kim HS, Yoo KH,
Jung KS, Song HN, Ku BM, Koh J, Bae YH, et al: A phase Ib/II study
of afatinib in combination with nimotuzumab in non-small cell lung
cancer patients with acquired resistance to gefitinib or erlotinib.
Clin Cancer Res. 22:2139–2145. 2016. View Article : Google Scholar
|
9
|
ENCODE Project Consortium: An integrated
encyclopedia of DNA elements in the human genome. Nature.
489:57–74. 2012. View Article : Google Scholar
|
10
|
Zhuo W, Zhang L, Zhu Y, Xie Q, Zhu B and
Chen Z: Valproic acid, an inhibitor of class I histone
deacetylases, reverses acquired Erlotinib-resistance of lung
adenocarcinoma cells: A Connectivity Mapping analysis and an
experimental study. Am J Cancer Res. 5:2202–2211. 2015.
|
11
|
Zhang S, Qin C, Cao G, Xin W, Feng C and
Zhang W: Systematic analysis of long noncoding RNAs in the
senescence-accelerated mouse prone 8 brain using RNA sequencing.
Mol Ther Nucleic Acids. 5:e3432016. View Article : Google Scholar
|
12
|
Djebali S, Davis CA, Merkel A, Dobin A,
Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F,
et al: Landscape of transcription in human cells. Nature.
489:101–108. 2012. View Article : Google Scholar
|
13
|
Li P, Zhang X, Wang H, Wang L, Liu T, Du
L, Yang Y and Wang C: MALAT1 is associated with poor response to
oxaliplatin-based chemotherapy in colorectal cancer patients and
promotes chemo-resistance through EZH2. Mol Cancer Ther.
16:739–751. 2017. View Article : Google Scholar
|
14
|
Lee TH, D'Asti E, Magnus N, Al-Nedawi K,
Meehan B and Rak J: Microvesicles as mediators of intercellular
communication in cancer - the emerging science of cellular
'debris'. Semin Immunopathol. 33:455–467. 2011. View Article : Google Scholar
|
15
|
Théry C, Ostrowski M and Segura E:
Membrane vesicles as conveyors of immune responses. Nat Rev
Immunol. 9:581–593. 2009. View
Article : Google Scholar
|
16
|
Santos JC, Ribeiro ML, Sarian LO, Ortega
MM and Derchain SF: Exosomes-mediate microRNAs transfer in breast
cancer chemo-resistance regulation. Am J Cancer Res. 6:2129–2139.
2016.
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar
|
18
|
Fustaino V, Presutti D, Colombo T,
Cardinali B, Papoff G, Brandi R, Bertolazzi P, Felici G and Ruberti
G: Characterization of epithelial-mesenchymal transition
intermediate/hybrid phenotypes associated to resistance to EGFR
inhibitors in non-small cell lung cancer cell lines. Oncotarget.
8:103340–103363. 2017. View Article : Google Scholar
|
19
|
Presutti D, Santini S, Cardinali B, Papoff
G, Lalli C, Samperna S, Fustaino V, Giannini G and Ruberti G: MET
gene amplification and MET receptor activation are not sufficient
to predict efficacy of combined MET and EGFR inhibitors in EGFR
TKI-resistant NSCLC cells. PLoS One. 10:e01433332015. View Article : Google Scholar
|
20
|
Xu SY, Huang X and Cheong KL: Recent
advances in marine algae polysaccharides: Isolation, structure, and
activities. Mar Drugs. 15:152017. View Article : Google Scholar
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
22
|
de Hoon MJ, Imoto S, Nolan J and Miyano S:
Open source clustering software. Bioinformatics. 20:1453–1454.
2004. View Article : Google Scholar
|
23
|
Xu TP, Liu XX, Xia R, Yin L, Kong R, Chen
WM, Huang MD and Shu YQ: SP1-induced upregulation of the long
noncoding RNA TINCR regulates cell proliferation and apoptosis by
affecting KLF2 mRNA stability in gastric cancer. Oncogene.
34:5648–5661. 2015. View Article : Google Scholar
|
24
|
Hirata H, Hinoda Y, Shahryari V, Deng G,
Nakajima K, Tabatabai ZL, Ishii N and Dahiya R: Long noncoding RNA
MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and
interacts with miR-205. Cancer Res. 75:1322–1331. 2015. View Article : Google Scholar
|
25
|
Schmidt M, Fernandez de Mattos S, van der
Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering BM and Medema RH:
Cell cycle inhibition by FoxO forkhead transcription factors
involves downregulation of cyclin D. Mol Cell Biol. 22:7842–7852.
2002. View Article : Google Scholar
|
26
|
Pefanis E, Wang J, Rothschild G, Lim J,
Kazadi D, Sun J, Federation A, Chao J, Elliott O, Liu ZP, et al:
RNA exosome-regulated long non-coding RNA transcription controls
super-enhancer activity. Cell. 161:774–789. 2015. View Article : Google Scholar
|
27
|
Kogure T, Lin WL, Yan IK, Braconi C and
Patel T: Intercellular nanovesicle-mediated microRNA transfer: A
mechanism of environmental modulation of hepatocellular cancer cell
growth. Hepatology. 54:1237–1248. 2011. View Article : Google Scholar
|
28
|
Wang Z, Wang N, Li W, Liu P, Chen Q, Situ
H, Zhong S, Guo L, Lin Y, Shen J, et al: Caveolin-1 mediates
chemoresistance in breast cancer stem cells via β-catenin/ABCG2
signaling pathway. Carcinogenesis. 35:2346–2356. 2014. View Article : Google Scholar
|
29
|
Ripamonti F, Albano L, Rossini A, Borrelli
S, Fabris S, Mantovani R, Neri A, Balsari A, Magnifico A and
Tagliabue E: EGFR through STAT3 modulates ΔN63α expression to
sustain tumor-initiating cell proliferation in squamous cell
carcinomas. J Cell Physiol. 228:871–878. 2013. View Article : Google Scholar
|
30
|
Rosell R, Moran T, Queralt C, Porta R,
Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M,
et al: Spanish Lung Cancer Group: Screening for epidermal growth
factor receptor mutations in lung cancer. N Engl J Med.
361:958–967. 2009. View Article : Google Scholar
|
31
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar
|
32
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, et al National Cancer Institute of Canada
Clinical Trials Group: Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005.
View Article : Google Scholar
|
33
|
Costa C, Molina MA, Drozdowskyj A,
Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R,
Massuti B, Wei J, Moran T, et al: The impact of EGFR T790M
mutations and BIM mRNA expression on outcome in patients with
EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the
randomized phase III EURTAC trial. Clin Cancer Res. 20:2001–2010.
2014. View Article : Google Scholar
|
34
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar
|
35
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar
|
36
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar
|
37
|
Li P, Zhang X, Wang L, Du L, Yang Y, Liu
T, Li C and Wang C: lncRNA HOTAIR contributes to 5FU resistance
through suppressing miR-218 and activating NF-κB/TS signaling in
colorectal cancer. Mol Ther Nucleic Acids. 8:356–369. 2017.
View Article : Google Scholar
|
38
|
Wu W, Wang Q, Yin F, Yang Z, Zhang W,
Gabra H and Li L: Identification of proteomic and metabolic
signatures associated with chemoresistance of human epithelial
ovarian cancer. Int J Oncol. 49:1651–1665. 2016. View Article : Google Scholar
|
39
|
Denzer K, Kleijmeer MJ, Heijnen HF,
Stoorvogel W and Geuze HJ: Exosome: From internal vesicle of the
multivesicular body to intercellular signaling device. J Cell Sci.
113:3365–3374. 2000.
|
40
|
van den Boorn JG, Dassler J, Coch C,
Schlee M and Hartmann G: Exosomes as nucleic acid nanocarriers. Adv
Drug Deliv Rev. 65:331–335. 2013. View Article : Google Scholar
|
41
|
Kucharzewska P and Belting M: Emerging
roles of extracellular vesicles in the adaptive response of tumour
cells to microenvironmental stress. J Extracell Vesicles. 2:22013.
View Article : Google Scholar
|
42
|
Mercer TR and Mattick JS: Structure and
function of long noncoding RNAs in epigenetic regulation. Nat
Struct Mol Biol. 20:300–307. 2013. View Article : Google Scholar
|
43
|
Yang H, Fu H, Xu W and Zhang X: Exosomal
non-coding RNAs: A promising cancer biomarker. Clin Chem Lab Med.
54:1871–1879. 2016. View Article : Google Scholar
|
44
|
Li Q, Shao Y, Zhang X, Zheng T, Miao M,
Qin L, Wang B, Ye G, Xiao B and Guo J: Plasma long noncoding RNA
protected by exosomes as a potential stable biomarker for gastric
cancer. Tumour Biol. 36:2007–2012. 2015. View Article : Google Scholar
|
45
|
Liu Y, Xu N, Liu B, Huang Y, Zeng H, Yang
Z, He Z and Guo H: Long noncoding RNA RP11-838N2.4 enhances the
cytotoxic effects of temozolomide by inhibiting the functions of
miR-10a in glioblastoma cell lines. Oncotarget. 7:43835–43851.
2016.
|
46
|
Tan Q, Yu Y, Li N, Jing W, Zhou H, Qiu S,
Liang C, Yu M and Tu J: Identification of long non-coding RNA 00312
and 00673 in human NSCLC tissues. Mol Med Rep. 16:4721–4729. 2017.
View Article : Google Scholar
|
47
|
Tan Q, Zuo J, Qiu S, Yu Y, Zhou H, Li N,
Wang H, Liang C, Yu M and Tu J: Identification of circulating long
non-coding RNA GAS5 as a potential biomarker for non-small cell
lung cancer diagnosisnon-small cell lung cancer, long non-coding
RNA, plasma, GAS5, biomarker. Int J Oncol. 50:1729–1738. 2017.
View Article : Google Scholar
|
48
|
Kim KM, Abdelmohsen K, Mustapic M,
Kapogiannis D and Gorospe M: RNA in extracellular vesicles. Wiley
Interdiscip Rev RNA. 8:82017. View Article : Google Scholar
|
49
|
Boukouris S and Mathivanan S: Exosomes in
bodily fluids are a highly stable resource of disease biomarkers.
Proteomics Clin Appl. 9:358–367. 2015. View Article : Google Scholar
|
50
|
Keller S, Ridinger J, Rupp AK, Janssen JW
and Altevogt P: Body fluid derived exosomes as a novel template for
clinical diagnostics. J Transl Med. 9:862011. View Article : Google Scholar
|